TY - JOUR
T1 - Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants
AU - Anraku, Yuki
AU - Kita, Shunsuke
AU - Onodera, Taishi
AU - Sato, Akihiko
AU - Tadokoro, Takashi
AU - Ito, Shiori
AU - Adachi, Yu
AU - Kotaki, Ryutaro
AU - Suzuki, Tateki
AU - Sasaki, Jiei
AU - Shiwa-Sudo, Nozomi
AU - Iwata-Yoshikawa, Naoko
AU - Nagata, Noriyo
AU - Kobayashi, Souta
AU - Kazuki, Yasuhiro
AU - Oshimura, Mitsuo
AU - Nomura, Takao
AU - Sasaki, Michihito
AU - Orba, Yasuko
AU - Suzuki, Tadaki
AU - Sawa, Hirofumi
AU - Hashiguchi, Takao
AU - Fukuhara, Hideo
AU - Takahashi, Yoshimasa
AU - Maenaka, Katsumi
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.
AB - Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.
UR - https://www.scopus.com/pages/publications/105000709108
UR - https://www.scopus.com/pages/publications/105000709108#tab=citedBy
U2 - 10.1038/s42003-025-07827-0
DO - 10.1038/s42003-025-07827-0
M3 - Article
C2 - 40121330
AN - SCOPUS:105000709108
SN - 2399-3642
VL - 8
JO - Communications Biology
JF - Communications Biology
IS - 1
M1 - 483
ER -